Project Details


Virginia G Piper Center for Personalized Diagnostics Virginia G. Piper Center for Personalized Diagnostics. The Partnership for Personalized Medicine (PPM) endeavors to improve patient outcomes and reduce long-term health care costs. The Virginia G. Piper Center for Personalized Diagnostics (CPD), one of two major infrastructure components comprising the PPM1 is working with experts in the fields of proteomics, imaging, nanotechnology, computing, informatics, and health economics to accomplish several goals. Namely, the Partnership will pursue the discovery of biomarkers, translate these biomarkers into diagnostic tools, demonstrate the value of these tools for clinical practice, and move these tools toward commercialization.2 In the past year, we have accomplished several significant organizational and staffing objectives in line with the goals approved for this project. The PPM has begun recruitment of faculty to fill critical positions within the CPD. We are in a late-stage negotiating phase to recruit Dr. Joshua LaBaer from Harvard University for the position of a CPD Piper Chair. We have also initiated discussions between the Biodesign Institute at Arizona State University (Biodesign) and the Translational Genomics Research Institute (TGen) to determine how to maximize the synergies of our partnership. The CPD is bringing together existing teams within the Biodesign Institute that possess technologies and/or competencies that are aligned with the PPMs3 goals. As an example of this collaborative team building, the Biodesign Institute (Randall Nelson, technical) and the BIO5 Institute at the University of Arizona (Craig Stump and Kurt Griffin, clinical) are engaged in studies investigating blood-borne markers of type 2 diabetes (T2D). Additionally, engineers and laboratory management from Biodesign are in discussions with TGen and the Fred Hutchinson Cancer Research Center (FHCRC) to assist with the design and implementation of automation to be used in the proteomics production facility laboratory The investment by Piper Trust is being leveraged by additional funding and will in turn leverage additional funding. By integrating existing Biodesign technical strengths and projects, the investment by Piper Trust is maximized as other funding is being brought to bear on goals important to the PPM. The research by Dr. Randall Nelson mentioned above, for example, is currently funded by Science Foundation Arizona. We also expect that the growing strength of the PPM and CPD will attract more funding. The success of the PPM with the Luxembourg government and ongoing discussions with the Singhealth Clinicians and the Ministry of Health of Singapore are early indications that a well-backed, well-led and well-orchestrated collaboration like the PPM resonates positively and leads to engagement. In addition, Dr. Nelson was able to obtain research funds from the Agilent Technologies Foundation for research closely aligned with the vision of PPM.
Effective start/end date12/7/076/30/13


  • Piper (Virginia G.) Charitable Trust: $12,050,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.